Eric Rovner to Muscarinic Antagonists
This is a "connection" page, showing publications Eric Rovner has written about Muscarinic Antagonists.
Connection Strength
3.497
-
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemp Clin Trials. 2018 07; 70:83-87.
Score: 0.572
-
New treatments for incontinence. Adv Chronic Kidney Dis. 2015 Jul; 22(4):279-88.
Score: 0.469
-
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008 Sep; 180(3):1034-41.
Score: 0.289
-
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008 Sep; 72(3):488-93.
Score: 0.289
-
Trospium chloride: the European experience. Expert Opin Pharmacother. 2006 Jul; 7(10):1373-80.
Score: 0.251
-
Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr; 6(4):653-66.
Score: 0.230
-
Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep. 2003 Oct; 4(5):385-90.
Score: 0.208
-
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol. 2002 Jan; 41(1):6-14.
Score: 0.184
-
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019 08; 36(8):1906-1921.
Score: 0.154
-
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
Score: 0.084
-
Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010 May; 105(9):1276-82.
Score: 0.079
-
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May; 105(9):1268-75.
Score: 0.079
-
Frequently asked questions in the evaluation and management of overactive bladder. J Fam Pract. 2009 Oct; 58(10 Suppl):S1-11; quiz S12.
Score: 0.079
-
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009 Sep; 182(3):1055-61.
Score: 0.078
-
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19):2319-28.
Score: 0.064
-
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006 Aug; 68(2):328-32.
Score: 0.063
-
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006 May; 97(5):1003-6.
Score: 0.062
-
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006 Apr; 67(4):731-6; discussion 736.
Score: 0.062
-
Pharmacologic management of urinary incontinence in the female. Minerva Ginecol. 2004 Aug; 56(4):327-47.
Score: 0.055
-
Trospium chloride in the management of overactive bladder. Drugs. 2004; 64(21):2433-46.
Score: 0.053
-
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021 Oct; 13(4):425-434.
Score: 0.044
-
BRL37344, a ?3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels. Urology. 2013 Sep; 82(3):744.e1-7.
Score: 0.026
-
The management of overactive bladder syndrome. BMJ. 2012 Apr 17; 344:e2365.
Score: 0.023